APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. (APVO) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $5.67 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.5% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Sector
Healthcare
Industry
Biotechnology